ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of immunotherapeutic products for oncology and infectious diseases. The company’s core technology platform is based on single-domain antibody fragments derived from shark immunoglobulins, known as VNARs, which offer high affinity, stability and tissue penetration. ABVC leverages this proprietary library to create novel antibody-based therapies and diagnostic agents designed to address unmet medical needs in both treatment and prevention.
The company’s pipeline encompasses a range of programs targeting key immune checkpoints and infectious disease antigens. In the immuno-oncology space, ABVC is developing VNAR candidates that modulate the PD-1/PD-L1 axis, CTLA-4 and other checkpoint pathways to enhance antitumor immune responses. In the infectious disease arena, the company is advancing prophylactic and therapeutic vaccine candidates against influenza strains and other pathogens, alongside development of monoclonal antibody therapeutics for bacterial toxins and viral targets. Several preclinical programs have demonstrated promising safety and efficacy profiles in animal models, supporting progression toward human clinical trials.
Headquartered in New York with R&D operations and strategic partnerships in China, ABVC BioPharma serves global markets through collaborations with academic institutions, contract research organizations and biomanufacturing facilities. The company maintains a flexible operating model that combines in-house discovery capabilities with outsourced development support to optimize resource allocation and accelerate timelines. ABVC’s international footprint enables access to diverse patient populations for clinical studies and fosters regulatory engagement across multiple jurisdictions.
Founded in 2010 and led by Dr. Wenbin Wang, founder and Chief Executive Officer, ABVC BioPharma is guided by a management team with extensive experience in antibody engineering, clinical development and commercialization. The board and scientific advisory committees include industry veterans who have overseen the approval and launch of biologic therapies. With its unique VNAR platform and a growing pipeline of immunotherapeutic assets, ABVC BioPharma aims to deliver first-in-class and best-in-class treatments that improve outcomes for patients worldwide.
